Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim prophylaxis for chemotherapy-induced neutropenia in diffuse large B-cell lymphoma
ChiCTR2100048196Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of grade 3 or higher neutropenia in cycle 1 and Adverse events. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2100048196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048196.